Active — Not RecruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

United States151 participantsStarted 2026-03-23

Plain-language summary

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Capable of providing written informed consent and complying with all trial procedures.
. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential).
. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening.
. HbA1c ≤6.5%.
. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula).
. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9).

Exclusion criteria

. History or current diagnosis of type 1 or type 2 diabetes mellitus.
. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication.
. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
. Use of GLP-1 agonist treatment within the last 6 months prior to screening.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Percentage Change in Body Weight from Baseline (Week 9) to Week 20

Timeframe: Baseline (Week 9) to Week 20

Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20

Timeframe: Baseline (Week 9) to Week 20

Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

Timeframe: Baseline (Week 9) to Week 20

Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

Timeframe: Baseline (Week 9) to Week 20

Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF

Timeframe: Baseline (Week 9) to Week 20

Trial details

NCT IDNCT07505303

SponsorEccogene

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-10-15

View on ClinicalTrials.gov More Adult Obesity trials

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Capable of providing written informed consent and complying with all trial procedures.
. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential).
. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening.
. HbA1c ≤6.5%.
. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula).
. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9).

Exclusion criteria

. History or current diagnosis of type 1 or type 2 diabetes mellitus.
. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication.
. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome.
. Use of GLP-1 agonist treatment within the last 6 months prior to screening.

What they're measuring

Percentage Change in Body Weight from Baseline (Week 9) to Week 20

Timeframe: Baseline (Week 9) to Week 20

Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20

Timeframe: Baseline (Week 9) to Week 20

Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

Timeframe: Baseline (Week 9) to Week 20

Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis

Timeframe: Baseline (Week 9) to Week 20

Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF

Timeframe: Baseline (Week 9) to Week 20